ADC Therapeutics SA

Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago rais

These are tough times for start-ups to raise cash on this side of the Atlantic but the money is there if you are developing a novel class of payloads in the hot space of antibody-drug conjugates (ADC)

Verona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w

While multiple new biologics for treating diffuse large B-cell lymphoma (DLBCL) have come onto the market in recent years, Pfizer Inc. is highlighting data in the disease for Adcetris (brentuximab v